Literature DB >> 24441526

Treatment of Hodgkin lymphoma: a 50-year perspective.

George P Canellos1, Saul A Rosenberg, Jonathan W Friedberg, T Andrew Lister, Vincent T Devita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24441526     DOI： 10.1200/JCO.2013.53.1194

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  50 in total

1.  Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.

Authors:  Massimo Federico; Stefano Luminari; Cinzia Pellegrini; Francesco Merli; Emanuela Anna Pesce; Stephane Chauvie; Letizia Gandolfi; Isabella Capodanno; Massimiliano Salati; Lisa Argnani; Pier Luigi Zinzani
Journal:  Haematologica       Date:  2015-12-24       Impact factor: 9.941

2.  Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues.

Authors:  M Huser; L Smardova; P Janku; I Crha; J Zakova; P Stourac; J Jarkovsky; J Mayer; P Ventruba
Journal:  J Assist Reprod Genet       Date:  2015-02-28       Impact factor: 3.412

3.  Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

Authors:  Carmelo Carlo-Stella; Francesca Ricci; Serena Dalto; Rita Mazza; Michele Malagola; Francesca Patriarca; Simonetta Viviani; Domenico Russo; Laura Giordano; Luca Castagna; Paolo Corradini; Armando Santoro
Journal:  Oncologist       Date:  2015-02-10

Review 4.  Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors:  Polina Shindiapina; Lapo Alinari
Journal:  Ther Adv Hematol       Date:  2018-03-05

Review 5.  The evolving role of response-adapted PET imaging in Hodgkin lymphoma.

Authors:  Michael Coyle; Lale Kostakoglu; Andrew M Evens
Journal:  Ther Adv Hematol       Date:  2016-04

Review 6.  FDG PET/CT imaging as a biomarker in lymphoma.

Authors:  Michel Meignan; Emmanuel Itti; Andrea Gallamini; Anas Younes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

7.  Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.

Authors:  Elif Hindié; Charles Mesguich; Krimo Bouabdallah; Noël Milpied
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08       Impact factor: 9.236

8.  Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.

Authors:  Guru Subramanian Guru Murthy; Aniko Szabo; Mehdi Hamadani; Timothy S Fenske; Nirav N Shah
Journal:  Oncologist       Date:  2019-08-29

9.  Baseline metabolic tumour volume in Hodgkin lymphoma: the prognostic value of accessory cells.

Authors:  Michel Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09       Impact factor: 9.236

Review 10.  Mechanisms underlying the association between obesity and Hodgkin lymphoma.

Authors:  Andreia Matos; Joana Marinho-Dias; Sofia Ramalheira; Maria José Oliveira; Manuel Bicho; Ricardo Ribeiro
Journal:  Tumour Biol       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.